Aspire Biopharma shares surge 21.28% premarket after $21M private placement to cut debt and regain Nasdaq compliance.

Aspire Biopharma surged 21.28% in premarket trading following the announcement of a $21 million private placement of Series A convertible preferred shares, with an initial $11 million raised through the issuance of 13,750 shares. The proceeds will reduce debt, fund operations, and support efforts to regain Nasdaq compliance with stockholders' equity requirements. The transaction, executed on February 6, 2026, also aims to strengthen the company’s balance sheet and advance its drug delivery technology development. While separate news about regaining Nasdaq’s minimum bid price requirement was reported later (February 10), the premarket rally was primarily driven by the financing announcement, which addresses critical financial and regulatory challenges.